Cambridge, MA, United States of America

Livnat Jerby


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Livnat Jerby: Innovator in Cancer Immunotherapy

Introduction

Livnat Jerby is a prominent inventor based in Cambridge, MA, known for his significant contributions to cancer research and immunotherapy. With a focus on detecting and modulating gene signatures related to immunotherapy resistance, Jerby has made strides in improving cancer treatment outcomes. He holds 2 patents that reflect his innovative approach to addressing challenges in cancer therapy.

Latest Patents

Jerby's latest patents include methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer. The subject matter disclosed is directed towards identifying novel gene signatures that predict overall survival in cancer patients. These gene signatures can be targeted therapeutically, providing a pathway for improved treatment strategies. Specifically, his research has identified a resistance program through comprehensive single-cell profiling studies in melanoma patients, validated in two large cohorts. His findings suggest that CDK4/6 inhibitors may reverse this resistance, with validation in melanoma cell lines and patient-derived co-culture models. The present invention offers a novel phased immunotherapy and CDK4/6 inhibitor combination therapy regimen, enhancing the potential for effective cancer treatment.

Career Highlights

Throughout his career, Livnat Jerby has worked with esteemed institutions such as the Broad Institute and the Massachusetts Institute of Technology. His work has significantly impacted the field of cancer research, particularly in understanding and overcoming drug resistance in melanoma.

Collaborations

Jerby has collaborated with notable figures in the field, including Aviv Regev and Orit Rozenblatt-Rosen. These collaborations have furthered his research and contributed to advancements in cancer immunotherapy.

Conclusion

Livnat Jerby's innovative work in cancer immunotherapy exemplifies the potential of targeted therapies in improving patient outcomes. His patents and research continue to pave the way for advancements in the treatment of cancer, showcasing the importance of innovation in this critical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…